On July 18 Fresenius Kabi announced that they are rolling out a line of generic contrast media products, starting immediately with Iodixanol Injection USP. 

The model was externally validated using more than 1,500 radiographs with real-world incidence of critically misplaced tubes. 

Citing low health literacy as a barrier between providers and patients in overcoming healthcare disparities, DenseBreast-info.org updated their breast density materials to include more patient-friendly, “simple language.”

Per Bayer’s communications, the contrast agent is manufactured at the same site in Berlin, Germany as the Ultravist that is intended for U.S. markets, but due to its intended distribution abroad it lacks current FDA-approved labeling. 

The researchers are now working on developing a qMRI method that can be incorporated into clinical settings, with an anticipated timeline of three to five years. 

Image sharpness was further improved when sharper reconstruction kernels were used, despite having higher noise levels.

The findings were discussed today at the annual meeting of the American Orthopaedic Society of Sports Medicine.

Individuals at high risk of pancreatic cancer benefit from annual imaging and have decreased mortality rates compared to those who forgo preventive screening.  

Using CBIRS decreased interpretation times despite the radiologists who utilized them having to review the additional information the system provided.

“CMS couldn’t have picked a worse time to cut Medicare payments to physicians,” said RBMA Executive Director Bob Still.